October 23, 2025
Willkie is advising funds managed by CVC Capital Partners, an existing shareholder of Sebia, a leading provider of specialty diagnostics, on the sale of a significant minority stake in Sebia to Warburg Pincus and CVC’s reinvestment in the company.
Sebia recently announced that Warburg Pincus entered into exclusive negotiations for the acquisition of a significant minority stake in Sebia. CVC funds, La Caisse (formerly CDPQ) and Téthys Invest are to remain significant investors following the transaction.
Sebia is a leading global provider of in vitro diagnostics, specializing in equipment and reagents for the screening and monitoring of various diseases.
Willkie previously advised CVC on its investment in Sebia in 2017 and represented Sebia in its acquisition of ORGENTEC Diagnostika in 2021.
CVC is a leading global private markets manager focused on private equity, secondaries, credit and infrastructure.
The Willkie team is led by partner Cédric Hajage with partners Grégoire Finance and Hugo Nocerino and associates Mathilde Faure, Sarah Bibas and Floriane Teillet.
Sebia recently announced that Warburg Pincus entered into exclusive negotiations for the acquisition of a significant minority stake in Sebia. CVC funds, La Caisse (formerly CDPQ) and Téthys Invest are to remain significant investors following the transaction.
Sebia is a leading global provider of in vitro diagnostics, specializing in equipment and reagents for the screening and monitoring of various diseases.
Willkie previously advised CVC on its investment in Sebia in 2017 and represented Sebia in its acquisition of ORGENTEC Diagnostika in 2021.
CVC is a leading global private markets manager focused on private equity, secondaries, credit and infrastructure.
The Willkie team is led by partner Cédric Hajage with partners Grégoire Finance and Hugo Nocerino and associates Mathilde Faure, Sarah Bibas and Floriane Teillet.
